Metformin inhibits salivary adenocarcinoma growth through cell cycle arrest and apoptosis

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Metformin exhibits anti-cancer properties in various malignancies.
• The impact of metformin on human salivary gland carcinoma remains largely unexplored.
• Salivary gland carcinomas represent a diverse group of rare head and neck cancers.

Purpose of the Study:

• To investigate the inhibitory effects of metformin, alone and in combination with an mTOR inhibitor (pp242), on human salivary adenocarcinoma cell growth.
• To elucidate the molecular mechanisms underlying metformin's action in salivary carcinoma cells.
• To evaluate the in vivo anti-tumor efficacy of metformin.

Main Methods:

• In vitro cell culture studies using human salivary adenocarcinoma cell lines (HSY and HSG).
• In vivo xenograft mouse models to assess tumor growth and response to treatment.
• Western blot analysis to evaluate the expression of MYC oncoprotein and p53 tumor suppressor gene.
• Time- and dose-dependent assays to determine metformin's effects.

Main Results:

• Metformin suppressed salivary adenocarcinoma cell growth in a time- and dose-dependent manner in vitro.
• Metformin treatment led to reduced expression of the MYC oncoprotein and restored p53 tumor suppressor gene expression.
• In vivo studies demonstrated increased tumor necrosis and reduced proliferation in xenograft tumors treated with metformin.
• Combination therapy with metformin and pp242 (mTOR inhibitor) showed enhanced inhibitory effects.

Conclusions:

• Metformin exhibits significant inhibitory effects on human salivary gland tumor cells, both in vitro and in vivo.
• Metformin's mechanism involves the downregulation of MYC and upregulation of p53, suggesting a distinct pathway from mTOR inhibition.
• The combination of metformin with an mTOR inhibitor potentiates anti-tumor activity, offering a potential therapeutic strategy for salivary gland carcinoma.